Accelerate Diagnostics, Inc
acceleratediagnostics.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2024 10-K, filed Mar 21, 2025. Its latest SEC filing is a NT 10-Q from Aug 18, 2025.
10-K for FY2024, filed Mar 21, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Sold diagnostic instruments and single-use test kits to hospitals and microbiology laboratories for identifying infectious pathogens and testing antibiotic susceptibility.
10-K for FY2024, filed Mar 21, 2025Accelerate Diagnostics, Inc. (“Accelerate”) is an in vitro diagnostics company dedicated to providing solutions that improve patient…View ↗
Our first system to address these challenges is the Accelerate Pheno® system. The Accelerate PhenoTest® BC Kit, which is the first test kit…View ↗
In 2017, we began selling the Accelerate Pheno system in hospitals in the United States, Europe and the Middle East. Consistent with our…View ↗
How Did They Make Money?
Customers were invoiced when instruments were installed or transferred to third-party distributors and when consumables shipped; service agreements were invoiced annually at the start of each service term and earned over the term.
10-K for FY2024, filed Mar 21, 2025
$11.7M
-
10-K for FY2024, filed Mar 21, 2025
$11.7M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Accelerate instrument and consumable revenue
Mix
10-K for FY2024, filed Mar 21, 2025 |
100%
FY2021: 99%
|
Accelerate instrument and consumable revenue, FY2024
$11.7M Sources
|
Mix |
|
Other revenue
|
−0.3%
FY2021: 1.3%
|
Other revenue, FY2024
−$33K Sources
|
|
|
Products
Mix
10-K for FY2024, filed Mar 21, 2025 |
87%
FY2021: 89%
|
Products, FY2024
$10.2M Sources
|
Mix |
|
Services
Recurring
10-K for FY2024, filed Mar 21, 2025 |
13%
FY2021: 11%
|
Services, FY2024
$1.5M Sources
|
Recurring |
Who Were Their Customers?
Healthcare diagnostics customers, primarily in the United States, bought instruments, consumables and service agreements. BD acted as the company's exclusive commercial agent and representative for ongoing product commercialization.
10-K for FY2024, filed Mar 21, 2025
The Company had one customer that represented 12% of the Company’s net sales for the year ended December 31, 2024 and no customers that…View ↗
Did Revenues Turn Into Profits?
No. It lost $50M in FY2024.
10-K for FY2024, filed Mar 21, 2025
How Were They Changing?
-
Aug 18, 2025
Sold certain assets and confirmed a liquidation plan
The sale closed, and the plan called for cancellation of all common shares.
Sources
8-K, filed Aug 18, 2025
On August 8, 2025, the Company Parties entered into an Amended and Restated Asset Purchase Agreement (the “A&R Asset Purchase Agreement”).…View ↗
-
May 28, 2025
The chief financial officer resigned
He notified the board of his resignation, effective June 30, 2025.
Sources
8-K, filed May 28, 2025
On May 21, 2025, David Patience notified the Board of Directors of Accelerate Diagnostics, Inc. (the “Company”) of his decision to resign…View ↗
-
May 12, 2025
Nasdaq moved to delist the common stock
The company did not plan to appeal; trading was set to be suspended and was expected to move over the counter.
Sources
8-K, filed May 12, 2025
On May 8, 2025, the Company received written notice (the “Delisting Notice”) from the Listing Qualifications Staff (the “Staff”) of The…View ↗
-
May 8, 2025
Filed for Chapter 11 and began an asset sale process
It agreed to sell substantially all assets to its secured noteholder, subject to court approval and competing bids.
Sources
8-K, filed May 8, 2025
In order to effectuate the transactions set forth herein, on May 8, 2025 (the “Petition Date”), Accelerate Diagnostics, Inc. (the…View ↗
Held flat. Revenue was $11.7M in FY2024, about the same as the $11.2M of FY2020.
Arc commercialization
Accelerate Arc moved from a development project with a planned research-use launch to a commercialized instrument and one-time-use test kit, and it received U.S. FDA approval.
10-K for FY2021, filed Mar 14, 2022 10-K for FY2024, filed Mar 21, 2025Current product development programs include the development of the Accelerate Arc system, an instrument and consumable aimed to improve…View ↗
Development focus
Research shifted from a planned next-generation Pheno system to WAVE as the primary development focus, with lower cost, higher throughput and a broader range of sample types as goals.
10-K for FY2021, filed Mar 14, 2022 10-K for FY2024, filed Mar 21, 2025Current product development programs include the development of the Accelerate Arc system, an instrument and consumable aimed to improve…View ↗
While we will continue to seek ways to improve the utility of our existing products, the primary focus of our current research and…View ↗
Who Did They Compete With?
Competes with BD, bioMerieux, Danaher, TREK, T2 Biosystems, Quantamatrix, Q-Linea, Specific Diagnostics, Lifescale, and Gradientech
10-K for FY2024, filed Mar 21, 2025The leading companies with automated microbiological testing products include BD, bioMerieux, Danaher and TREK. These companies provide…View ↗
Loading...
